QUECTEL-WIRELESS
Quectel Wireless Solutions, a global IoT solutions provider, today announces that, according to a recent milestone report by Finite State, an independent third-party cybersecurity firm, nearly 95% of all Quectel modules shipped to the United States since the beginning of 2022 have industry-leading security scores based on penetration testing and binary analysis by Finite State.
The report highlights a notable enhancement in Quectel's security position, expanding the number of modules tested and with scores across the tested modules improving from an average of 33 to 18, up from an average of 62 to 24 in previous testing. This represents a substantial improvement, as both the initial and revised scores significantly surpass the industry average of 98 with the lowest (best) score of 10. Further, the number of and severity of vulnerabilities Finite State did identify in Quectel products or modules are significantly less than the industry standard and revealed a very limited attack surface. Those issues Finite State did discover have been quickly remedied by Quectel.
This advanced phase of testing leverages Finite State's security technologies and expertise to conduct an exhaustive third-party evaluation of Quectel's modules. The advanced testing encompasses an array of sophisticated security assessments designed to fortify Quectel's modules against the evolving landscape of cyber threats, including binary analysis of numerous Quectel products and both penetration testing and binary analysis of several Quectel cellular modules.
"Entering this next phase of security testing with Finite State underscores our relentless pursuit of the highest security standards for our products," stated Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "Our continued collaboration is a reflection of our commitment to exceed industry security expectations, ensuring our customers benefit from the most secure and reliable communication modules available – tested and verified by one of the most trusted US cyber security firms. We’re thrilled that the latest report from Finite State demonstrates our commitment and progress."
The continued integration of Finite State into Quectel’s transparency and security program reaffirms Quectel’s commitment to pioneering unparalleled security practices in the IoT and telecommunications sectors. Quectel has made a measurable improvement in key areas such as the security health of the code, the sophistication of the vulnerability management process, and the transparency of its software supply chain.
The program is strategically designed with three key goals to address the pressing issues in cybersecurity today:
- Implementing the Finite State Platform into Quectel's DevSecOps procedures, which enhances firmware binary analysis, manages vulnerabilities efficiently, and offers specific recommendations for remediation.
- Developing and sharing Software Bill of Materials (SBOM) and Vulnerability Exploitability Exchange (VEX) documents for each of Quectel's products, which promotes a transparent environment and provides critical insights into the software components of Quectel's devices along with any vulnerabilities they may contain.
- Conducting comprehensive manual penetration tests by Finite State's expert Red Team, which augments automated testing methods and delivers detailed security evaluations for Quectel's product line.
Matt Wyckhouse, CEO of Finite State, commented, "Progressing to this next phase of security testing demonstrates Quectel’s commitment to leading the industry with transparent, rigorous cybersecurity practices. Quectel's willingness to subject their products to such rigorous scrutiny is commendable and sets a new industry standard to further safeguard the IoT ecosystem."
The outcome of this continued engagement is anticipated to enhance the security framework of Quectel's modules and inspire a shift towards more rigorous security standards across the telecommunications industry. Quectel is dedicated to sharing insights and best practices gleaned from this process, contributing to a safer, more secure digital future.
In addition to the activity with Finite State, Quectel is actively pursuing collaboration with multiple standards-setting organizations to enhance and commit to a more rigorous set of security requirements. This initiative aims to achieve key security certifications from both industry and governmental bodies, underlining Quectel's dedication to advancing security standards within the sector.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318703729/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera1.6.2025 14:00:00 CEST | Press release
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpointAll key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomesNo serious adverse events considered related to rusfertide were reportedRusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary e
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom